Janus激酶抑制剂:银屑病关节炎患者的安全性。

Q2 Medicine

The Journal of rheumatology. Supplement Pub Date : 2022-03-15 DOI:10.3899/jrheum.211329

P. Nash

{"title":"Janus激酶抑制剂:银屑病关节炎患者的安全性。","authors":"P. Nash","doi":"10.3899/jrheum.211329","DOIUrl":null,"url":null,"abstract":"Janus kinase inhibitors ( JAKi; or Jakinibs) have become widely prescribed around the world for a variety of immune-mediated inflammatory diseases, including psoriatic arthritis. A previous noninferiority surveillance study of patients aged > 50 years with rheumatoid arthritis and ≥ 1 additional cardiac risk factor raised a number of safety concerns. This review focuses on available safety data from peer-reviewed publications, as well as the most recent presentations from major conferences highlighting JAKi-associated adverse effects. The safety data for several types of JAKi are reviewed. The latest available safety data for tofacitinib, upadacitinib, filgotinib, deucravacitinib, and brepocitinib is presented. In addition, the findings from the oral surveillance study will be discussed to put safety concerns into context.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis.\",\"authors\":\"P. Nash\",\"doi\":\"10.3899/jrheum.211329\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Janus kinase inhibitors ( JAKi; or Jakinibs) have become widely prescribed around the world for a variety of immune-mediated inflammatory diseases, including psoriatic arthritis. A previous noninferiority surveillance study of patients aged > 50 years with rheumatoid arthritis and ≥ 1 additional cardiac risk factor raised a number of safety concerns. This review focuses on available safety data from peer-reviewed publications, as well as the most recent presentations from major conferences highlighting JAKi-associated adverse effects. The safety data for several types of JAKi are reviewed. The latest available safety data for tofacitinib, upadacitinib, filgotinib, deucravacitinib, and brepocitinib is presented. In addition, the findings from the oral surveillance study will be discussed to put safety concerns into context.\",\"PeriodicalId\":35278,\"journal\":{\"name\":\"The Journal of rheumatology. Supplement\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of rheumatology. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3899/jrheum.211329\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of rheumatology. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3899/jrheum.211329","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

摘要

Janus激酶抑制剂;雅克替尼(Jakinibs)在世界各地被广泛用于治疗各种免疫介导的炎症性疾病，包括银屑病关节炎。先前一项针对年龄> 50岁且伴有≥1个额外心脏危险因素的类风湿关节炎患者的非劣效性监测研究提出了许多安全性问题。本综述的重点是来自同行评议出版物的现有安全性数据，以及来自主要会议的最新报告，这些报告强调了与jaki相关的不良反应。综述了几种JAKi的安全性数据。介绍了tofacitinib、upadacitinib、filgotinib、deucravacitinib和brepocitinib的最新可用安全性数据。此外，将讨论口腔监测研究的结果，以便将安全问题纳入背景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis.

Janus kinase inhibitors ( JAKi; or Jakinibs) have become widely prescribed around the world for a variety of immune-mediated inflammatory diseases, including psoriatic arthritis. A previous noninferiority surveillance study of patients aged > 50 years with rheumatoid arthritis and ≥ 1 additional cardiac risk factor raised a number of safety concerns. This review focuses on available safety data from peer-reviewed publications, as well as the most recent presentations from major conferences highlighting JAKi-associated adverse effects. The safety data for several types of JAKi are reviewed. The latest available safety data for tofacitinib, upadacitinib, filgotinib, deucravacitinib, and brepocitinib is presented. In addition, the findings from the oral surveillance study will be discussed to put safety concerns into context.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Journal of rheumatology. Supplement Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The Journal of Rheumatology is a monthly international serial edited by Duncan A. Gordon, The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 36 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.